Industry: Healthcare
Published Date: April-2025
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 190
Report ID: PMRREP35189
The global cold laser therapy market size is projected to reach USD 130.8 million in 2025 and attain a CAGR of 5.2% from 2025 to 2032, reaching USD 187.1 million by 2032. According to Persistence Market Research the growth is fueled by the increasing prevalence of chronic pain, musculoskeletal disorders, and sports injuries, coupled with the rising demand for non-invasive, drug-free treatment options.
According to the 2023 National Health Interview Survey (NHIS), 24.3% of U.S. adults reported chronic pain, with 8.5% experiencing high-impact chronic pain that limits daily activities. This widespread condition imposes a significant economic burden, with pain-related healthcare costs in the U.S. estimated at $565 to $635 billion annually, according to a report published by the National Center for Biotechnology Information (NCBI) and PubMed Central (PMC). To address this, technological advancements such as multi-wavelength laser systems and home-use cold laser devices are improving treatment accessibility and effectiveness, potentially reducing long-term healthcare expenses.
Key Industry Highlights:
|
Global Market Attribute |
Key Insights |
|
Cold Laser Therapy Market Size (2025E) |
US$ 130.8 Mn |
|
Market Value Forecast (2032F) |
US$ 187.1 Mn |
|
Projected Growth (CAGR 2025 to 2032) |
5.2% |
|
Historical Market Growth (CAGR 2019 to 2024) |
4.1% |
The rising prevalence of chronic pain and musculoskeletal disorders is a key highlight. An NIH study published recently highlights high rates of persistent pain among U.S. adults, fueling demand for non-invasive treatment options. In April 2024, Domer Technology launched advanced cold laser devices for both human and veterinary use, while in May 2024, APEX Brain Centers explored Low-Level Laser Therapy (LLLT) for brain health. The shift toward drug-free pain management and the effectiveness of cold laser therapy in reducing inflammation and promoting tissue repair accelerate its adoption in healthcare.
The adoption of cold laser therapy faces restraints due to competition from well-established alternative treatments such as physical therapy, ultrasound therapy, shockwave therapy, and PRP (platelet-rich plasma) injections. These modalities are widely used in pain management and rehabilitation, often preferred due to greater clinical validation, broader insurance coverage, and physician familiarity. For instance, shockwave therapy, commonly used for musculoskeletal conditions such as plantar fasciitis and tendon injuries, has shown high success rates in promoting tissue regeneration and pain relief. Alternatively, PRP injections use patient’s platelets to accelerate healing have become increasingly popular for sports injuries and osteoarthritis further limits the penetration of cold laser therapy.
Expanding home-use cold laser therapy devices presents a significant opportunity for market growth. The increasing availability of compact, user-friendly, handheld lasers drives consumer adoption beyond clinical settings. FDA-approved devices like Erchonia’s EVRL for pain management and iRestore hair growth laser for hair restoration highlight the potential of at-home treatments. As consumers seek convenient, non-invasive solutions, the demand for home-use cold laser therapy is expected to rise, creating new revenue streams for manufacturers, and expanding market reach.
Continuous laser devices are projected to lead the product segment in 2025, accounting for approximately 55.6% market share. Their dominance stems from the ability to deliver a steady and focused laser beam, allowing deep tissue penetration crucial for cellular repair and inflammation reduction. These devices are preferred by healthcare professionals due to their precise dosage control, ensuring consistent and reliable treatment outcomes.
A notable example is the FX 635 Laser, manufactured by Erchonia Corporation, which is FDA-cleared for chronic low back pain and heel pain treatment. The FX 635 uses continuous laser technology provides non-invasive pain relief by stimulating cellular function and reducing inflammation making it a preferred choice for pain management and rehabilitation. The effectiveness and versatility of continuous laser devices such as the FX 635 further solidifies positions them as the dominating technology.
In 2025, handheld cold laser devices are projected to dominate the modality segment, capturing approximately 59.3% market share. Their portability and ease of use make them ideal for both clinical and home settings. For example, devices such as the TerraQuant Pro by Multi Radiance Medical features multiple applicators and adjustable settings, enhances treatment precision for localized pain and injuries.
The growing demand for convenient, non-invasive therapy solutions drives the preference for handheld devices over tabletop alternatives. While both are non-invasive, handheld devices offer greater flexibility, allowing practitioners and patients to easily target specific areas in remote regions. Their lightweight and compact design makes them more adaptable for use across different treatment environments, whereas tabletop models are typically restricted to clinical settings limiting their accessibility for home-based therapy.
North America is projected to account for 43.3% of the global cold laser therapy market by 2025, driven by regulatory approvals and technological advancements. The FDA’s approval of the first cold ablative fiber laser in April 2022, developed by Acclaro Corporation with its UltraClear™ system, marked a key milestone, expanding applications in pain management, dermatology, and rehabilitation. Additionally, industry leaders like Multi Radiance Medical and Erchonia Corporation continue to introduce innovative cold laser devices, such as the TerraQuant Pro and FX 635, which are widely used in musculoskeletal therapy, sports medicine, and chronic pain relief. The increasing adoption of handheld and multi-wavelength laser systems further strengthens North America’s position as a key market for cold laser technology.
Europe is estimated to account for 23.3% market share in 2025 driven by advancements in medical laser technology and a growing preference for non-invasive treatments. The EU Medical Device Regulation (MDR) ensures high safety and efficacy, boosting adoption among healthcare providers.
The clinical trials in February 2024 validated cold laser therapy’s effectiveness, with a randomized controlled trial showing that LLLT significantly reduces post-endodontic pain, reinforcing its role in pain management. Government-backed initiatives further drive demand, with Germany, France, and the U.K. leading adoption in physiotherapy clinics, sports medicine centers, and hospitals. For example, Celluma Light Therapy, an LLLT device, received EU MDR certification, highlighting the region’s focus on safety and effectiveness.
The East Asia market is projected to attain 18.5% market share driven by rapid technological advancements and increasing adoption of laser-based medical treatments. China and India are leading this expansion, integrating cutting-edge laser technologies into healthcare. In November 2024, the establishment of the Chinese Association for Laser in Medicine and Surgery (CALMS) in Shijiazhuang marked a significant step in China’s commitment to advancing laser-based medical technologies, including cold laser therapy. Simultaneously, India's focus on innovation is evident in the development of Class 4 laser therapy machines, enhancing pain relief and rehabilitation treatments. These innovations, showcased at international medical exhibitions highlight the region's increasing adoption of cold laser therapy, positioning East Asia as a key growth hub in the global market.
In Latin America, cold laser therapy also known as low-level laser therapy (LLLT) is gaining traction as a non-invasive treatment for various medical conditions. In Mexico, the Lyme Mexico Clinic highlights its benefits in tissue regeneration, mitochondrial energy production, improved circulation, and lymphatic drainage. Similarly, research from Brazil’s Optics and Photonics Research Center (CEPOF) identified LLLT as the most effective treatment for tinnitus, a condition affecting 750 million people worldwide, due to its anti-inflammatory properties and ability to enhance peripheral circulation. As more healthcare providers in Mexico, Brazil, and Argentina integrate laser-based therapies, Latin America continues to expand its adoption of cold laser technology for pain management, rehabilitation, and neurological treatments.
The Middle East and Africa (MEA) region is emerging as a lucrative market for cold laser therapy, driven by the increasing demand for non-invasive pain management solutions and advancements in medical laser technology. January 2025 marked a significant step in expanding laser-based treatment options for chronic pain relief in Kenya with the introduction of MLS® Laser Therapy. In the UAE, leading healthcare facilities are incorporating low-level laser therapy (LLLT) for musculoskeletal disorders and rehabilitation, reflecting the region’s growing adoption of advanced therapeutic solutions. These developments underscore the MEA region's increasing role in the global market, making it a key area for technological expansion and clinical adoption.
The global cold laser therapy market is fragmented, with key players such as Multi Radiance Medical, Erchonia Corporation, THOR Photomedicine, and Bioflex Laser competing across various segments. The market includes a diverse range of handheld and tabletop laser devices. Technological advancements are driving improvements in treatment precision, accessibility, and user adoption.
|
Report Attribute |
Details |
|
Historical Data/Actuals |
2019 – 2024 |
|
Forecast Period |
2025 - 2032 |
|
Market Analysis Units |
Value: US$ Mn, Volume: As Applicable |
|
Geographical Coverage |
|
|
Segmental Coverage |
|
|
Competitive Analysis |
|
|
Report Highlights |
|
|
Customization and Pricing |
Available upon request |
By Product Type
By Modality
By Use
By Application
By End-user
By Region
To know more about delivery timeline for this report Contact Sales
The global cold laser therapy market is estimated to increase from US$ 130.8 Mn in 2025 to US$ 187.1 Mn in 2032.
The growing demand for non-invasive pain management solutions and advancements in laser technology are propelling the global cold laser therapy market.
The market is projected to record a CAGR of 5.2% during the forecast period from 2025 to 2032.
An opportunity in the cold laser therapy market lies in the growing demand for home-use devices, expanding accessibility and treatment convenience for consumers.
Major players include Erchonia Corporation, MKW Lasersystem GmbH, Meditech International Inc., Zimmer Medizin Systems, and Enovis Corporation, among others.
